AltMountain

Superstring Capital Management LP

New York, NY · CRD 305743
Hedge fund manager

Superstring Capital Management LP is an SEC-registered investment adviser based in New York, NY that reports managing 1 hedge fund on Form ADV. It reports $339.5 million in regulatory assets under management. Its private funds, of all types, hold $315.7 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +28.7% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +114.5% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$339.5 millionForm ADV Item 5.F
Gross assets of private funds
$315.7 millionAll private fund types, Form ADV
Hedge funds managed
12 private funds in total
Employees
5Form ADV Item 5.A
Registration
SEC-registered adviserCRD 305743
Latest Form ADV
03/30/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+28.7%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+114.5%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$158.4 million32 positions, 2026-06-30
$74$144$215Q3 2024Q1 2025Q3 2025Q1 202613F est. $215S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+26.7%+14.8%
Q1 2026+1.6%-4.6%
Q4 2025+43.8%+2.4%
Q3 2025+38.4%+7.8%
Q2 2025+12.9%+10.4%
Q1 2025-16.1%-4.5%
Q4 2024-17.9%+2.1%
Q3 2024+7.7%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 35 share positions ($199,517,915) reported by Superstring Capital Management LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Cogent Biosciences Inc9.59%
  • Axsome Therapeutics Inc.9.47%
  • Trevi Therapeutics Inc7.07%
  • Genmab A/s6.54%
  • Climb Bio Inc5.28%
  • Zai Lab LTD4.79%
  • Adlai Nortye LTD4.72%
  • Revolution Medicines Inc4.30%
  • Celldex Therapeutics Inc New3.94%
  • Immunovant Inc3.76%
StockValue% of 13F portfolioSharesShares vs prior quarter
Cogent Biosciences Inc$19,129,0049.59%597,408+74.03%
Axsome Therapeutics Inc.$18,897,2099.47%102,485+90.08%
Trevi Therapeutics Inc$14,103,6537.07%984,892+87.88%
Genmab A/s$13,044,9926.54%365,662-15.08%
Climb Bio Inc$10,532,1105.28%918,231+76.22%
Zai Lab LTD$9,552,7544.79%362,671+132.76%
Adlai Nortye LTD$9,414,6884.72%588,418+6.50%
Revolution Medicines Inc$8,576,5844.30%41,784-18.16%
Celldex Therapeutics Inc New$7,859,1983.94%242,493-15.68%
Immunovant Inc$7,503,2473.76%222,121+6.60%
Urogen Pharma LTD$7,491,8473.75%184,392-3.62%
United Therapeutics Corp Del$7,218,5173.62%13,321+85.74%
Legend Biotech Corp$7,107,8713.56%357,359New
Definium Therapeutics Inc$6,719,9123.37%176,561-6.23%
Roivant Sciences LTD$6,540,2523.28%178,842+597.97%
Vir Biotechnology Inc$6,469,8213.24%578,696-32.21%
Ionis Pharmaceuticals Inc$5,908,9362.96%132,339New
Savara Inc$5,251,9362.63%1,017,817+4.13%
Sagimet Biosciences Inc$4,179,2992.09%423,006New
Abivax SA$2,972,5801.49%30,020New
Ginkgo Bioworks Holdings Inc$2,855,3551.43%222,553New
Spyre Therapeutics Inc$2,672,8591.34%30,022New
Bright Minds Biosciences Inc$2,393,6021.20%48,045+57.75%
Kiniksa Pharmaceuticals Intl$2,363,9431.18%31,684+67.93%
Taysha Gene Therapies Inc$2,013,1271.01%413,373New
Latigo Biotherapeutics Inc$1,472,5730.74%88,178New
Oruka Therapeutics Inc$1,286,4970.64%15,446New
Maplight Therapeutics Inc$1,205,5180.60%118,304-5.68%
Madrigal Pharmaceuticals Inc$1,057,8120.53%2,099New
Cabaletta Bio Inc$993,4310.50%517,412-59.53%
Xenon Pharmaceuticals Inc$985,3860.49%26,496New
Tonix Pharmaceuticals Hldg C$727,4610.36%74,688+17.35%
Boundless Bio Inc$517,6670.26%206,242+272.57%
Grail Inc$453,7090.23%3,238New
Biomea Fusion Inc$44,5650.02%225,872-9.65%

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 12 new positions, 9 sold out, 14 increased, 9 reduced and 0 unchanged.

Number of positions (a count, not dollars)

  • New positions12
  • Increased14
  • Unchanged0
  • Reduced9
  • Sold out9

New positions

StockValueShares
Legend Biotech Corp$7,107,871357,359
Ionis Pharmaceuticals Inc$5,908,936132,339
Sagimet Biosciences Inc$4,179,299423,006
Abivax SA$2,972,58030,020
Ginkgo Bioworks Holdings Inc$2,855,355222,553
Spyre Therapeutics Inc$2,672,85930,022
Taysha Gene Therapies Inc$2,013,127413,373
Latigo Biotherapeutics Inc$1,472,57388,178
Oruka Therapeutics Inc$1,286,49715,446
Madrigal Pharmaceuticals Inc$1,057,8122,099
Xenon Pharmaceuticals Inc$985,38626,496
Grail Inc$453,7093,238

Sold out

StockValue at Jun 30, 2026Shares held then
Oric Pharmaceuticals Inc$4,397,814406,077
Vaxcyte Inc$3,882,67766,793
Beone Medicines LTD$3,497,43712,273
Sionna Therapeutics Inc$2,778,23263,156
Aclaris Therapeutics Inc$1,363,101257,675
Cybin Inc$1,351,243204,424
Protara Therapeutics Inc$463,966121,457
Faeth Therapeutics Inc$354,37514,175
Vyne Therapeutics Inc$39,86861,269

Largest increases

StockChange in sharesChangeValue nowShares now
Axsome Therapeutics Inc.+48,569+90.08%$18,897,209102,485
Cogent Biosciences Inc+254,124+74.03%$19,129,004597,408
Trevi Therapeutics Inc+460,668+87.88%$14,103,653984,892
Roivant Sciences LTD+153,219+597.97%$6,540,252178,842
Zai Lab LTD+206,858+132.76%$9,552,754362,671
Climb Bio Inc+397,149+76.22%$10,532,110918,231
United Therapeutics Corp Del+6,149+85.74%$7,218,51713,321
Kiniksa Pharmaceuticals Intl+12,817+67.93%$2,363,94331,684
Bright Minds Biosciences Inc+17,589+57.75%$2,393,60248,045
Adlai Nortye LTD+35,917+6.50%$9,414,688588,418
Immunovant Inc+13,753+6.60%$7,503,247222,121
Boundless Bio Inc+150,886+272.57%$517,667206,242
Savara Inc+40,357+4.13%$5,251,9361,017,817
Tonix Pharmaceuticals Hldg C+11,040+17.35%$727,46174,688

Largest reductions

StockChange in sharesChangeValue nowShares now
Vir Biotechnology Inc-274,989-32.21%$6,469,821578,696
Genmab A/s-64,938-15.08%$13,044,992365,662
Revolution Medicines Inc-9,269-18.16%$8,576,58441,784
Cabaletta Bio Inc-761,240-59.53%$993,431517,412
Celldex Therapeutics Inc New-45,090-15.68%$7,859,198242,493
Definium Therapeutics Inc-11,721-6.23%$6,719,912176,561
Urogen Pharma LTD-6,921-3.62%$7,491,847184,392
Maplight Therapeutics Inc-7,128-5.68%$1,205,518118,304
Biomea Fusion Inc-24,128-9.65%$44,565225,872

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Private funds reported on Form ADV (2)

As reported in the adviser's Form ADV filed Mar 28, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌‌‌⁠